3,4-dimethylbenzoic acid | CAS:619-04-5

We serve 3,4-dimethylbenzoic acid CAS:619-04-5 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
3,4-dimethylbenzoic acid

Chemical Name:3,4-dimethylbenzoic acid
CAS.NO:619-04-5
Synonyms:3,4-dimethylbenzoic acid
1-Carboxy-3,4-dimethylbenzene
3,4-dimethylbenzene carboxylic acid
o-Xylene-4-carboxylic Acid
Molecular Formula:C9H10O2
Molecular Weight:150.17400
 
Physical and Chemical Properties:
Density:1.116
Melting point:163-165ºC
Boiling point:294.6ºC
Flash point:134.9ºC
Index of Refraction:1.549
 
Specification:
Appearance:Off-white solid
Assay:≥98.0%
Moisture:≤0.5%
 
Packing:25 kg/drum, can also be packaged according to customer requirements
Storage:Store in a cool, ventilated place
Application:Organic synthesis intermediate



Contact us for information like 3,4-dimethylbenzoic acid chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,o-Xylene-4-carboxylic Acid physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,1-Carboxy-3,4-dimethylbenzene Use and application,1-Carboxy-3,4-dimethylbenzene technical grade,usp/ep/jp grade.


Related News: Slow business: Due to fear — and travel warnings — fewer people want to travel to China.Pivaloyl chloride manufacturer In addition, with the increase of environmental protection pressure, nearly one hundred Beijing pharmaceutical companies have gathered in the Bohai Bay, and the raw material drug base in northern China has taken shape.Methyl (2E)-3-[3-(trifluoromethyl)phenyl]acrylate supplier In addition, with the increase of environmental protection pressure, nearly one hundred Beijing pharmaceutical companies have gathered in the Bohai Bay, and the raw material drug base in northern China has taken shape.Methyl 5-fluoro-2-methyl-3-nitrobenzoate vendor An analysis of the top 20 global companies by R&D spend for 2018 shows that companies with expensive late-stage pipeline drugs are spending significant proportions of their annual revenue on R&D.An analysis of the top 20 global companies by R&D spend for 2018 shows that companies with expensive late-stage pipeline drugs are spending significant proportions of their annual revenue on R&D.